Morgan Stanley Upgrades Agilent Technologies Inc to Overweight

Brokerage firm Morgan Stanley Upgrades its rating on Agilent Technologies Inc(A). The shares have been rated Overweight. Previously, the analysts had a Equal-Weight rating on the shares. The rating by the stock financial advisor at Morgan Stanley was issued on Mar 15, 2017 in a research report to their Investors and Clients.

Agilent Technologies Inc (A) made into the market gainers list on Fridays trading session with the shares advancing 0.49% or 0.26 points. Due to strong positive momentum, the stock ended at $53.31, which is also near the day’s high of $53.53. The stock began the session at $53.06 and the volume stood at 19,36,902 shares. The 52-week high of the shares is $54.82 and the 52 week low is $38.59. The company has a current market capitalization of $17,182 M and it has 32,23,00,910 shares in outstanding.

Agilent Technologies Inc(A) last announced its earnings results on Feb 14, 2017 for Fiscal Year 2017 and Q1.Company reported revenue of $1.067B. Analysts had an estimated revenue of $1.050B. Earnings per share were $0.53. Analysts had estimated an EPS of $0.49.

Several Insider Transactions has been reported to the SEC. On Feb 21, 2017, Patrick Kaltenbach (Sr Vice President) sold 3,771 shares at $51.68 per share price.Also, On Feb 16, 2017, Didier Hirsch (Sr. VP and CFO) sold 22,258 shares at $51.50 per share price.On Dec 12, 2016, Mark Doak (Sr. Vice President) sold 3,969 shares at $46.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Agilent Technologies Inc. is engaged in the life sciences diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments software services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business the diagnostics and genomics business and the Agilent CrossLab business. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business the genomics business and the nucleic acid solutions business. The Company’s Agilent CrossLab business segment combines its analytical laboratory services and consumables business.

Add Comment